The FDA is extending its review of Johnson & Johnson's Doribax for pneumonia by three months. Regulators say the company has provided new information about the drug that needs to be assessed. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/fda-extends-review-timeline-additional-indication-antibiotic-doribax-tm